Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Bhag Karamchandani who wrote (4309)	5/15/1998 3:56:00 PM
From: Bhag Karamchandani	Read Replies (1) \| Respond to of 6136

Is any one tracking the relative merits of AG3340 and Imclone's CC225 ( epidermal Growth Factor)currently in Phase II trials. Also, Matrix has a phase II trial (intradose) where Phase One results (they claim)showed decrease of 50% in tumor volume and 30% increase in volume of necrotic tumor issues? The Matrix product is more a drug delivery mechanism and is mentioned here not as a "relative merit" issue but rather as a relative effective cancer treatment issue. I continue to believe that most cancer treatments, to be effective, will require multiple simultaneous therapies.Hence my enthusiasm for AGPH trial which uses AG3340 in conjunction with chemotherapy agents. I do not personally own shares in any of these companies- but wish to hear from those who have a better understanding of the drugs and delivery mechanisms than I have. My apologies to those who may consider my questions a digression. Thanks.

To: Bhag Karamchandani who wrote (4309)	5/15/1998 5:10:00 PM
From: Peter Singleton	Read Replies (1) \| Respond to of 6136

oops, thanks Andreas for pointing this out. Intradose results were for 50% decrease in tumor volume, not 50% increase ... too late to edit the preceding note. : (